DHPA

  • Home
  • About Us
    • Leadership
      • Executive Committee
      • Board Members
    • DHPA Members
    • Contact Us
    • Join Us
  • Advocacy
    • Patient Access to Independent GI Care
      • Colorectal Cancer Screening
    • Diversity Equity and Inclusion
    • Modernizing the Stark Law
    • Saving the IOASE
    • Pathology Services Utilization
  • Resources
    • Independent GI Careers
    • Research
    • Fact Sheets
    • Letters to Policymakers
    • Leadership Webinar Series
  • Newsroom
    • Press Releases
    • DHPA in the News
    • GI News Round Up
  • Take Action

November 30, 2020

DHPA Opposes Most Favored Nation Rule Announced by CMS

Misguided policy will dramatically restrict access to infusion medications and force patients into more expensive care setting

Washington, DC – The Digestive Health Physicians Association® (DHPA®) opposes the Most Favored Nation (MFN) rule recently announced by the Centers for Medicare & Medicaid Services (CMS). The MFN Rule could dramatically restrict patient access to infusion medications administered in physician offices, especially for patients with Crohn’s disease and ulcerative colitis, which are both major categories of inflammatory bowel disease (IBD).

Under the MFN model, reimbursements will be determined by the lowest price that drug manufacturers receive in any one of 22 different countries. The MFN rule also changes the current payment model for life-saving medications by providing a flat administration fee for each dose, which CMS projects will result in a 20 percent cut to gastroenterologists.

“Hundreds of thousands of patients are treated in DHPA member practices with medications that would be subject to this complicated scenario that bases reimbursements on what it costs to acquire the drugs in another country,” said Dr. James Weber, DHPA president and board chair. “We are greatly troubled about what this will mean for our patients. In its own rule, CMS projects that 19 percent of Part B drug utilization will be eliminated by 2023 because patients will no longer be able to access the drugs subject to this international pricing scheme.”

In addition to patient access concerns, DHPA is concerned that the MFN rule could threaten the viability of medical practices, especially smaller practices and those in rural or underserved areas. If private practices can no longer afford to administer these drugs, this policy is likely to force patients to seek care in the more expensive hospital setting where Medicare and patients pay dramatically more for drug administration. Such a result runs counter to policymakers’ desire to keep care out of the more expensive outpatient hospital setting.

“The effects of this rule could be seriously detrimental to our healthcare system, especially during the COVID-19 pandemic,” said Dr. Glenn Littenberg, DHPA chair of health policy. “Not only will the MFN rule increase overall costs to Medicare by forcing our patients into higher-cost settings, but hospitals are the last places we should be sending our patients with chronic conditions until the pandemic is under control.”

Dr. Weber stated that DHPA looks forward to working with policymakers on policies that lower costs without compromising the quality of patient care, but voiced concern that CMS has bypassed the normal regulation notice-and-comment rulemaking process. A nationwide demonstration project is set to go into effect on January 1, 2021, which is 20 days before the rule’s required comment period closes.

“This is far too serious an issue—with vast health policy and patient care implications—for CMS to have fast-tracked this rule without obtaining input from providers and patients,” said Dr. Weber.

Filed Under: Newsroom, Press Releases, Protecting Patient Access to Integrated GI Care in the Independent Setting

Member Spotlight

Adult Gastroenterology Associates is a single-specialty GI and hepatology practice serving Tulsa and much of Northeastern Oklahoma, with physicians who specialize in colon cancer screening, treatment of GERD, IBD, and treatment of diseases of the liver and pancreas.

Learn more at:
www.tulsagastro.com

Become a Member

    Is your practice interested in promoting and preserving accessible, high quality and cost-efficient care in the independent GI medical setting? Contact us today about joining DHPA.

    Recent News

    • DHPA Recommends MACRA Improvements to Bipartisan Group of U.S. Representatives

    • New Study in Gastro Journal: GI Patients Consider Telehealth to be the Same as In-Person Visits

    • DHPA Comment Letter on OPPS/ASC Proposed Rule for Calendar Year 2023

    • DHPA Comment Letter on MPFS Proposed Rule for Calendar Year 2023

    • Webinar: Supporting Career Development for Women in GI

    • Reducing the Burden of Colorectal Cancer: AGA Position Statements

    • Dr. Latha Alaparthi Named President & Board Chair of DHPA

    • Independent Healthcare Grants and Charitable Donations (Abbvie)

    • Community Grant Program (Walmart Foundation)

    Digestive Health Physicians Association, Inc.
    10770 Columbia Pike, Suite 400
    Silver Spring, Maryland, 20901
    © 2020 DHPA

    Follow @DHPAnews
    Tweets by DHPAnews

    Copyright © 2023 · Executive Pro Theme on Genesis Framework · WordPress · Log in